Prelude Capital Management’s Coya Therapeutics COYA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$593K Hold
101,330
0.04% 462
2026
Q1
$399K Buy
101,330
+49,060
+94% +$229K 0.03% 604
2025
Q4
$303K Buy
52,270
+16,500
+46% +$100K 0.02% 790
2025
Q3
$204K Hold
35,770
0.02% 938
2025
Q2
$206K Hold
35,770
0.02% 805
2025
Q1
$231K Hold
35,770
0.02% 842
2024
Q4
$205K Hold
35,770
0.01% 981
2024
Q3
$231K Hold
35,770
0.01% 1000
2024
Q2
$217K Hold
35,770
0.02% 954
2024
Q1
$355K Hold
35,770
0.02% 810
2023
Q4
$265K Hold
35,770
0.02% 795
2023
Q3
$137K Buy
+35,770
New +$142K 0.01% 961

Other funds holding COYA

Prelude Capital Management's COYA Position: Q2 2026 in Review

Prelude Capital Management held its Coya Therapeutics (COYA) position steady in Q2 2026 at 101,330 shares worth $593K. The position accounts for 0.04% of the portfolio, ranked #462.

Prelude Capital Management first reported a position in COYA in Q3 2023 and has held it in 12 quarters since. 54 funds tracked by Wall St. Rank hold COYA as of Q2 2026.

  • Prelude Capital Management held 101,330 shares of Coya Therapeutics worth $593K as of Q2 2026.
  • Prelude Capital Management left its Coya Therapeutics share count unchanged in Q2 2026.
  • Coya Therapeutics made up 0.04% of Prelude Capital Management's portfolio in Q2 2026, its #462 holding.
  • Prelude Capital Management first reported a position in Coya Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 54 funds tracked by Wall St. Rank held Coya Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.